Orexin-A

Also known as: Hypocretin-1, OXA

A neuropeptide regulating wakefulness, appetite, and reward.

Overview

Orexin-A is a 33 amino acid neuropeptide produced by hypothalamic neurons. It plays crucial roles in wakefulness, energy homeostasis, and reward processing. Orexin deficiency causes narcolepsy.

Mechanism of Action

Binds OX1R and OX2R receptors to promote wakefulness and arousal. Regulates sleep-wake transitions, feeding behavior, and reward circuitry. Stabilizes wake states.

Pharmacokinetics

Does not readily cross BBB; intranasal administration preferred for CNS effects. Endogenous levels fluctuate with circadian rhythm.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Alertness

Dose

30-100 mcg

Frequency

Morning

Duration

As needed

Intranasal administration

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Cognitive alertness

Synergy: Wakefulness plus cognitive enhancement

Research Areas

NarcolepsySleep DisordersCognitive EnhancementObesity

Key Research Findings

  • 1Orexin replacement improves narcolepsy symptoms
  • 2Enhanced cognitive performance and alertness
  • 3Intranasal delivery shows CNS effects in humans
  • 4Stabilizes sleep architecture

Side Effects & Contraindications

Reported Side Effects

  • Anxiety
  • Insomnia
  • Increased appetite

Contraindications

  • Anxiety disorders
  • Insomnia

Safety Considerations

May cause anxiety or insomnia at high doses. Avoid evening administration.

Storage Requirements

Store at -20C. Protect from light.

Scientific References

Quick Reference

Sequence
QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTLG-NH2
Molecular Weight
3561 g/mol
Half-Life
~30 minutes
Bioavailability
Intranasal for CNS effects
Research Stage
clinical phase 2
Administration
Intranasal